BHCM
ADMA icon

Brevan Howard Capital Management’s ADMA Biologics ADMA Stock Holding History

Brevan Howard Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$577K Buy
68,896
+48,104
+231% +$439K ﹤0.01% 1378
2026
Q1 		$187K Sell
20,792
-225,980
-92% -$3.57M ﹤0.01% 1918
2025
Q4 		$4.5M Buy
+246,772
New +$4.16M 0.05% 262
2025
Q3 		– Sell
-32,202
Closed -$586K – 1908
2025
Q2 		$586K Buy
32,202
+17,823
+124% +$363K ﹤0.01% 1283
2025
Q1 		$285K Buy
+14,379
New +$249K ﹤0.01% 876

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Brevan Howard Capital Management's ADMA Position: Q2 2026 in Review

Brevan Howard Capital Management increased its ADMA Biologics (ADMA) stake by 231% in Q2 2026, buying an estimated $439K and bringing the position to 68,896 shares worth $577K. The position accounts for ﹤0.01% of the portfolio, ranked #1378.

Brevan Howard Capital Management first reported a position in ADMA in Q1 2025 and has held it in 5 quarters since. The position peaked at $4.5M in Q4 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Brevan Howard Capital Management held 68,896 shares of ADMA Biologics worth $577K as of Q2 2026.
  • Brevan Howard Capital Management bought 48,104 ADMA Biologics shares in Q2 2026, an estimated $439K.
  • ADMA Biologics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1378 holding.
  • Brevan Howard Capital Management first reported a position in ADMA Biologics in Q1 2025 and has held it in 5 quarters since.
  • Brevan Howard Capital Management's ADMA Biologics position peaked at $4.5M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.